Document is current
Any future updates will be listed below
-
Authors
Nicholls, Stephen J.
Tofé, Santiago
le Roux, Carel W.
D’Alessio, David A.
Wiese, Russell J.
Pavo, Imre
Brown, Katelyn
Weerakkody, Govinda J.
Zeytinoglu, Meltem
Romera, Irene C.
-
Funding
Funding for this research was provided by:
Eli Lilly and Cmpany
- License Information
-
More Information
Article History
Received: 7 November 2023
Accepted: 29 January 2024
First Online: 10 February 2024
Declarations
:
: SURPASS-1, SURPASS-2, SURPASS-3, SURPASS-4, and SURPASS-5 trials were conducted in accordance with the International Conference on Harmonisation Guidelines for Good Clinical Practice and the Declaration of Helsinki. All patients provided signed informed consent and protocols were approved by local ethical review boards.
: Not applicable.
: SJN has received research support from AstraZeneca, New Amsterdam Pharma, Amgen, Anthera, Eli Lilly and Company, Esperion, Novartis, Cerenis, The Medicines Company, Resverlogix, InfraReDx, Roche, Sanofi-Regeneron and LipoScience and is a consultant for AstraZeneca, Amarin, Akcea, Eli Lilly and Company, Anthera, Omthera, Merck, Takeda, Resverlogix, Sanofi-Regeneron, CSL Behring, Esperion, Boehringer Ingelheim and Vaxxinity. ST has served on advisory boards and received consulting fees from Boehringer Ingelheim, Eli Lilly and Company, Johnson and Johnson, Novo Nordisk, and Sanofi. CWlR serves on advisory boards of Novo Nordisk A/S, Herbalife, GI Dynamics, Eli Lilly and Company, Johnson & Johnson, Glia, and Boehringer Ingelheim and was gifted stockholdings in September 2021 and divested all stock holdings in Keyron in September 2021. He continues to provide scientific advice to Keyron for no remuneration. DAD receive research support from Eli Lilly and Company and participates on the Diabetes Advisory Board for Eli Lilly and Company and the steering committee for the tirzepatide CVOT. RJW, IP, KB, GJW, MZ and ICR are employees and shareholders of Eli Lilly and Company.
